Related Experiment Video
Updated: Apr 15, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease
Meng Wei1, Meirong Huang, Shubao Chen
1Department of Pediatric Cardiology, Shanghai Children's Medical Center, Medical Institute, Shanghai Jiaotong University, 1678, Dongfang Road, Shanghai, 200127, China.
Insights
Kawasaki disease patients unresponsive to intravenous immunoglobulin (IVIG) are more likely to develop coronary artery lesions (CAL). Early, sufficient IVIG dosing and monitoring risk factors like lymph node enlargement can prevent non-response and CAL.
Area of Science:
- Pediatrics
- Immunology
- Cardiology
Background:
- Kawasaki disease (KD) is a critical pediatric illness.
- Intravenous immunoglobulin (IVIG) is a primary treatment for KD.
- Coronary artery lesions (CAL) are a major complication of KD.
Purpose of the Study:
- To identify risk factors for IVIG non-response in KD patients.
- To examine the relationship between IVIG non-response and CAL development.
- To inform early intervention strategies for KD management.
Main Methods:
- Retrospective analysis of 1953 KD patients' clinical records (1998-2007).
- Univariate and multivariate statistical analyses were employed.
- Logistic regression identified independent risk factors for IVIG non-response.
Main Results:
- 6.8% of patients were IVIG non-responders; 18.6% developed CAL.
- IVIG non-responders had a significantly higher incidence of CAL (31.3% vs. 17.6%).
- Sufficient IVIG doses reduced non-response rates (5.2% vs. 18.1%).
- Independent risk factors for non-response included lymph node enlargement, CAL, high ESR (≥75 mm/h), and high PLT count (≥530 × 10(9)/L).
Conclusions:
- IVIG non-response is linked to increased CAL risk in KD.
- Early and sufficient IVIG dosing is crucial for preventing non-response and CAL.
- Cervical lymph node enlargement, elevated ESR, and high PLT count predict non-response to sufficient IVIG doses.
- Consider combination therapy (hormones/immunosuppressants) for high-risk patients to mitigate non-response and CAL.
Abstract:
To investigate the relationship between the risk factors associated with intravenous immunoglobulin (IVIG) non-response and the incidence of coronary artery lesions (CAL) in patients with Kawasaki disease (KD). A retrospective study was performed on clinical records of 1953 KD patients who were admitted to hospitals in Shanghai, China, between 1998 and 2007. Related clinical and laboratory findings were studied using univariate and multivariate statistical analyses. Of the 1953 KD patients, 133 (6.8 %) were unresponsive to IVIG therapy, and 356 (18.6 %) developed CAL. The incidence of CAL in the non-responsive IVIG group was significantly different from that in the responsive IVIG group (31.3 vs. 17.6 %). The incidence of IVIG non-response was significantly lower in the patients who received sufficient doses of IVIG than in the patients who received insufficient doses (5.2 vs. 18.1 %). A logistic regression analysis of 1295 patients who received sufficient IVIG doses indicated that cervical lymph node enlargement, CAL, erythrocyte sedimentation rate (ESR) ≥75 mm/h, and platelet count (PLT) ≥530 × 10(9)/L were independent risk factors of IVIG non-response. IVIG non-responders are prone to develop CAL. Initiation of therapy with sufficient IVIG doses at the early stage of the disease is crucial for preventing IVIG non-response. Lymph node enlargement, ESR ≥75 mm/h, and PLT count ≥530 × 10(9)/L are independent risk factors for predicting non-response to sufficient IVIG doses. For patients with the tendency of being unresponsive to IVIG therapy, treatment using sufficient IVIG doses combined with hormones or immunosuppressive agents should be considered to reduce the incidence of IVIG non-response and CAL.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Bioequivalence studies: Biowaivers
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

